This study validated six risk scores for ischemic stroke in patients with AF across the spectrum of kidney function. The Modified CHADS2 score showed most consistent predictive performance in all kidney function categories.

Adrian Hernandez gives background information about iron metabolism and discusses results from outcome trials on iron deficiency in HF.

Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

Using data of the LEADER trial, this post hoc analysis demonstrated that in T2DM patients with high CV and moderate renal risk, a reduction in UACR of >30% was associated with lower risk of CV and renal outcomes.

This subanalysis of PARAGON-HF showed that efficacy outcomes with sacubitril/valsartan compared to valsartan were independent of MRA use in patients with HFpEF.

This post hoc analysis of the CREDENCE trial suggests that canagliflozin, compared to placebo, slowed the rate of eGFR decline in patients with an eGFR level of <30 ml/min/1.73m² at randomization.

A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 mL/min/1.73 m² was performed. Prof. Bakris shares the results of this analysis.

AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.

AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.

AHA 2020 The primary CV endpoint was reduced by the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared to placebo in patients with diabetes and CKD, and in patients with diabetes and ADHF.

In the FIDELIO-DKD trial, finerenone lowered the risk of CKD progression and CV events in patients with CKD and type 2 diabetes compared to placebo.